Kimo C. Stine

OverviewAI-generated summary

Kimo C. Stine's research has focused on investigating potential therapeutic interventions and understanding disease mechanisms. A significant area of his work involves gene therapy for severe hemophilia A, with publications detailing the analysis of the Alta study, including 104-week and 2-year results. His research also explores biomarkers for cardiotoxicity, specifically investigating microRNA-34a-5p as a preclinical biomarker for doxorubicin-induced chronic cardiotoxicity and examining delayed-onset subclinical cardiotoxicity in mouse models.

Further investigations include the identification of genetic factors related to disease, such as a novel germline TP53 mutation in a patient with Li-Fraumeni syndrome. Stine has also contributed to studies on predictive risk factors for myocardial injury in children treated with anthracyclines. His work is supported by a network of collaborators, including Vikrant Vijay and Bounleut Phanavanh from the National Center for Toxicological Research, and David P. Douglass from the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications.

With an h-index of 27 and over 2,400 citations across 83 publications, Stine is recognized as a highly cited researcher. His recent activity indicates an ongoing commitment to advancing medical knowledge in these areas.

Metrics

• h-index: 27
• Publications: 83
• Citations: 2,438